AnthracyclinesChemotherapy, AdjuvantNaphthacenesAntibiotics, AntineoplasticDaunorubicinAdjuvants, ImmunologicBreast NeoplasmsDoxorubicinRadiotherapy, AdjuvantAclarubicinCarubicinNogalamycinAdjuvants, PharmaceuticAntineoplastic Combined Chemotherapy ProtocolsRazoxaneEpirubicinDisease-Free SurvivalFluorouracilTreatment OutcomeNeoplasm Recurrence, LocalTamoxifenFreund's AdjuvantCombined Modality TherapyAntineoplastic AgentsNeoplasm StagingIdarubicinMenogarilAntineoplastic Agents, HormonalLevamisoleSurvival AnalysisPrognosisLeukemia P388CyclophosphamideLymphatic MetastasisTaxoidsSurvival RateBridged CompoundsAromatase InhibitorsFollow-Up StudiesLeucovorinRetrospective StudiesDrug Administration ScheduleColonic NeoplasmsNeoadjuvant TherapyMethotrexateStreptomycesNeoplasm MetastasisReceptors, EstrogenReceptor, erbB-2Randomized Controlled Trials as TopicTime FactorsMastectomyExtravasation of Diagnostic and Therapeutic MaterialsClinical Trials as TopicAdenocarcinomaCardiotoxinsKaplan-Meier EstimateLeukemia L1210Heart DiseasesIntercalating AgentsFree RadicalsAntimetabolites, AntineoplasticProspective StudiesTriazolesNitrilesPaclitaxelPostmenopauseDeoxycytidineTumor Markers, BiologicalReceptors, ProgesteroneAntibodies, Monoclonal, HumanizedMultivariate AnalysisProportional Hazards ModelsDose-Response Relationship, DrugLymph Node ExcisionCardiomyopathiesRecurrenceLymph NodesMitomycinPremenopauseColorectal NeoplasmsRectal NeoplasmsInfusions, IntravenousOrganoplatinum CompoundsDrug Resistance, NeoplasmMedical OncologyNeoplasms, Hormone-DependentSarcoma, Endometrial StromalCisplatinGoserelinPredictive Value of TestsNeoplasmsDrug ResistanceVincristineImmunohistochemistryP-GlycoproteinMelanomaAluminum HydroxideRisk FactorsMice, Inbred BALB C